Biochemistry & Analytical Biochemistry

The role of micro-RNAs as predictors of response to Tamoxifen treatment in breast cancer patients

International Conference on Clinical Chemistry & Laboratory Medicine

October 17-18, 2016 Chicago, USA

Emiel Janssen

Stavanger University Hospital, Norway

Posters & Accepted Abstracts: Biochem Anal Biochem

Abstract:

endocrine therapy, via tamoxifen or aromatase inhibitor, is a key treatment strategy to control and eradicate breast cancer. However, resistance to endocrine therapy leads to breast cancer relapse. The recent extension of adjuvant tamoxifen treatment up to 10 years actualizes the need for monitoring breast cancer development during treatment. MicroRNAs are promising biomarkers that may fill the gap between preclinical knowledge and clinical observations regarding endocrine resistance. MicroRNAs regulate gene expression by posttranscriptional repression or degradation of mRNA, most often leading to gene silencing. MicroRNAs have been identified directly in the primary tumor, but also in the circulation of breast cancer patients. The few available studies investigating microRNA in patients suggest that seven microRNAs (miR-10a, miR-26, miR-30c, miR-126a, miR-210, miR-342 and miR-519a) play a role in tamoxifen resistance. Ingenuity Pathway Analysis (IPA) reveals that these seven microRNAs interact more readily with oestrogen receptor (ER) independent pathways than ER-related signaling pathways. Some of these pathways are targetable (e.g. PIK3A) suggesting that microRNAs as biomarkers of endocrine resistance may have clinical value. Validation of the role of these candidate microRNAs in large prospective studies is warranted. Currently a microRNA profiling study has been performed in ER-pos breast cancer patients with and without recurrences under tamoxifen treatment. Results from the literature and the profiling studies will be compared with each other.

Biography :

Email: emilius.adrianus.maria.janssen@sus.no